Clik here to view.
Ocular Therapeutix slashes workforce following FDA rejection
Ocular Therapeutix (NSDQ:OCUL) revealed yesterday that it plans to cut 26 jobs across the Bedford, Mass.-based company – about 19% of its workforce. The effort to reorganize comes just weeks after the...
View ArticleClik here to view.
Intersect ENT tops EPS, sales estimates in Q2
Shares in Intersect ENT (NSDQ:XENT) surged today after the drug-device company beat expectations on Wall Street with its second quarter results. The Menlo Park, Calif.-based company posted a loss of...
View ArticleClik here to view.
Aerie Pharmaceuticals misses Q2 EPS by a penny
Shares in Aerie Pharmaceuticals (NSDQ:AERI) held steady today after the pharmaceutical company missed EPS estimates on Wall Street with its second quarter results. The Irvine, Calif.-based company...
View ArticleClik here to view.
Pacira misses on Q2 sales, earnings
Shares in Pacira Pharmaceuticals (NSDQ:PCRX) fell slightly today after the pharmaceutical company missed expectations on Wall Street with its second quarter results. The Parsippany, N.J.-based company...
View ArticleClik here to view.
Teva lowers outlook after Q2 EPS misses estimates
(Reuters) – Israeli drugs group Teva Pharmaceuticals (NYSE:TEVA) reported a steeper than expected drop in second-quarter earnings on Thursday, due to weaker prices in the United States, and cut its...
View ArticleClik here to view.
DOJ subpoenas Mallinckrodt over opioids
Mallinckrodt Pharmaceuticals (NYSE:MNK) said yesterday that it received a subpoena from the U.S. Dept. of Justice requesting information related to its marketing practices and sales of opioids. The...
View ArticleClik here to view.
Mobile prescription delivery service launches in DC
CaryRx announced today the launch of its same-day prescription drug delivery service for people in the Washington, D.C. metro area. The Washington-based company is hoping that the convenience of its...
View ArticleClik here to view.
National Cancer Institute to back research efforts for local delivery of chemo
The National Cancer Institute and the National Institutes of Health said last month that it plans to fund up to five projects involving novel methods to locally deliver chemopreventative drugs. The two...
View ArticleClik here to view.
Insulet Q2 sales tops estimates
Shares in Insulet (NSDQ:PODD) rose today after the company met earnings expectations on Wall Street and beat sales estimates with its second quarter results. The Billerica, Mass.-based company posted...
View ArticleClik here to view.
Study: Injectable antiretroviral therapy proves as effective as oral treatment
Injectable antiretroviral therapy may be as effective as standard oral treatment in patients with HIV, according to the results of a Phase II clinical trial. The 286-patient study, published in The...
View ArticleClik here to view.
MannKind combines inhaled insulin with One Drop’s digital diabetes tech
MannKind Corp. (NSDQ:MNKD) and One Drop said today that the group launched its A-One trial evaluating MannKind’s inhaled insulin, Afrezza, for use with One Drop’s digital diabetes management platform....
View ArticleClik here to view.
Pulmatrix beats Q2 EPS by a penny
Shares in Pulmatrix (NSDQ:PULM) fell last week even though the biopharmaceutical company beat expectations on Wall Street with its second quarter results. The Lexington, Mass.-based company posted a...
View ArticleClik here to view.
Teva wins FDA nod for Qvar RediHaler device
Teva Pharmaceuticals (NYSE:TEVA) said today that the FDA approved its Qvar RediHaler breath-actuated inhaler for the maintenance treatment of asthma in patients ages 4 and older. The device, which is...
View ArticleClik here to view.
FDA approves Jazz Pharmaceutical’s liposomal AML chemotherapy
Jazz Pharmaceuticals (NSDQ:JAZZ) said today that the FDA approved its Vyxeos injectable liposome for the treatment of adults with two types of acute myeloid leukemia. Vyxeos is the first product...
View ArticleClik here to view.
Kaleo launches program to get Auvi-Q allergy auto-injector into schools
Kaleo said today that it launched a new program to offer its epinephrine auto-injector, Auvi-Q, free-of-charge to all public elementary schools in the U.S. The program is slated to give up to four...
View ArticleClik here to view.
FDA approves 4-year intrauterine device
Allergan (NYSE:AGN) and women’s health nonprofit Medicines360 said today that the FDA approved a supplemental new drug application to extend the duration of use for Liletta, a levonorgestrel-releasing...
View ArticleClik here to view.
Endo swings to Q2 loss on $775m pelvic mesh set-aside
Endo International (NSDQ:ENDP) posted a net loss in the second quarter of this year, citing charges like the $775 million it has set aside to resolve 22,000 remaining lawsuits relating to the company’s...
View ArticleClik here to view.
Rebiotix launches late-stage superbug trial for microbiome-based drug
Rebiotix isn’t a traditional drugmaker. Its products are alive. The 32-person company, based in Roseville, Minn., is developing a microbiome-based therapy to prevent recurrent Clostridium difficile...
View ArticleClik here to view.
Mallinckrodt beats Q2 earnings, misses on revenue
Shares in Mallinckrodt Pharmaceuticals (NYSE:MNK) fell today after the company beat earnings estimates but missed on revenue with its second quarter results. The U.K.-based company posted profits of...
View ArticleClik here to view.
Anika Therapeutics touts Hyalofast scaffold, stem cell combo
Anika Therapeutics (NSDQ:ANIK) touted data today from a study evaluating the use of its Hyalofast biodegradable, hyaluronic acid-based scaffold in combination with autologous adult mesenchymal stem...
View Article